FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ABRAMS MICHAEL S
2. Date of Event Requiring Statement (MM/DD/YYYY)
5/10/2021 

3. Issuer Name and Ticker or Trading Symbol

Arch Therapeutics, Inc. [ARTH]
(Last)        (First)        (Middle)

235 WALNUT STREET, SUITE 6
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
CFO and Treasurer /
(Street)

FRAMINGHAM, MA 01702      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)  (1)5/2/2031 Common Stock 500000 $0.1329 D  

Explanation of Responses:
(1) 33.3% of the shares subject to the option shall vest on the one-year anniversary of the the grant date, and 1/24th of the remaining unvested shares subject to this grant shall vest commencing on each f the next twenty-four (24) monthly anniversaries thereater, subject to the Exectuive's continued service for the Company through each vesting date. In the event of a Change of Control (such as defined in the Plan), then, in any such case, 100% of the number of unvested Shares then subject to the grant shall accelerate and become vested as of the date of such event.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
ABRAMS MICHAEL S
235 WALNUT STREET, SUITE 6
FRAMINGHAM, MA 01702


CFO and Treasurer

Signatures
/s/ Michael S. Abrams5/10/2021
**Signature of Reporting PersonDate

Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Arch Therapeutics (QB) Charts.
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Arch Therapeutics (QB) Charts.